Patient P-02575

Synthetic patientMETA-24 · Day 94 · 55–64 · F · baseline S14Open companion preview

Therapy response

Favorable

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 86 ME-01 recommended — Monitoring Escalation ME-01
Day 87 Patient accepted — Started ME-01 in the companion
Day 90 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 69.

Primary contributors, last 14 days

GI instability+14
Inflammatory activity+9
Toxicity+9
Treatment adherence-8
Nutritional resilience-6

What helped?

Monitoring Escalation ME-01Day 86
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
91% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
- WearableSleep 5.9 h, below personal baseline
Autonomic recovery ↓65
- WearableResting HR 74 bpm
- Wearable939 steps/day
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 28/100
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑25
- BloodInflammatory load index 62
Drug metabolism and exposure ↑20
- BloodToxicity index 57

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.7 · butyrate capacity 28/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 39 ms
Sleep: 6.1 h
Steps: 911
Resting HR: 73 bpm

Daily log: GI score 62, nutritional resilience 39, adherence 76.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02115	42%	S14	GI-04	improved	75
P-02102	38%	S14	GI-04	improved	64
P-02060	37%	S14	GI-04	improved	54
P-02318	36%	S14	GI-04	no change	62
P-02666	36%	S14	ME-01	improved	51
P-02252	33%	S02	—	—	65
P-02298	32%	S14	GI-04	improved	65
P-02460	32%	S18	GI-04	improved	59
P-02165	31%	S14	ME-01	improved	59
P-02299	31%	S14	GI-04	improved	59
P-02078	30%	S04	—	—	56
P-02265	30%	S07	GI-04	no change	67